
StartupHealth & bio
Invitris
Creating new protein-based drugs at scale
About
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
BiotechNanotechnologyDrug discovery
Facts
- Website
- invitris.com
- City
- Munich
- Country
- Germany
- YC batch
- Winter 2023
- Team
- 6 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in Munich
Is this your company?
Claim this profile
Free and instant: prove you run invitris.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Invitris across the site
- Open roles listed on the Hiring board
- A followed link back to your website
For your website
A rank card with Invitris's standing on Labspie, or a simple badge. Both link to this profile and update themselves.


